🇺🇸 Current Formulation of Oritavancin in United States

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

FDA authorised Current Formulation of Oritavancin on 6 August 2014

Marketing authorisation

FDA — authorised 6 August 2014

Application: NDA206334
Marketing authorisation holder: MELINTA THERAP
Local brand name: ORBACTIV
Indication: POWDER — INTRAVENOUS
Status: approved

Read official source →

Frequently asked questions

Is Current Formulation of Oritavancin approved in United States?

Yes. FDA authorised it on 6 August 2014.

Who is the marketing authorisation holder for Current Formulation of Oritavancin in United States?

MELINTA THERAP holds the US marketing authorisation.